Keyphrases
Programmed Death-ligand 1 (PD-L1)
100%
Thyroid Transcription factor-1 (TTF-1)
100%
Retrospective multicenter Study
100%
Non-squamous NSCLC
100%
Chemoimmunotherapy
60%
Non-squamous Non-small Cell Lung Cancer
40%
Therapeutic Efficacy
30%
Programmed Death-ligand 1 Expression
30%
Pemetrexed
30%
Programmed death-1 Inhibitor
30%
Monotherapy
20%
Confidence Interval
20%
Propensity Score Matching
20%
No Significant Difference
10%
Non-small Cell Lung Cancer (NSCLC)
10%
Treatment Efficacy
10%
Progression-free Survival
10%
Clinical Impact
10%
Antitumor Efficacy
10%
Overall Scores
10%
Tumor Proportion Score
10%
Medicine and Dentistry
Immunotherapy
100%
Non-Small Cell Lung Cancer
100%
Homeobox Protein Nkx 2.1
100%
Programmed Death 1 Ligand 1
100%
Chemoimmunotherapy
66%
Non Small Cell Lung Cancer
44%
Combination Therapy
44%
Pemetrexed
33%
Neoplasm
22%
Monotherapy
22%
Progression Free Survival
11%
Propensity Score Matching
11%
Pharmacology, Toxicology and Pharmaceutical Science
Immunotherapy
100%
Programmed Death 1 Ligand 1
100%
Homeobox Protein Nkx 2.1
100%
Combination Therapy
44%
Non Small Cell Lung Cancer
44%
Pemetrexed
33%
Neoplasm
22%
Monotherapy
22%
Progression Free Survival
11%